egfr overexpression in squamous cell carcinoma of the penis by Lavens, N. et al.
4
Cu r r e n t On C O l O g y —VO l u m e  17, nu m b e r 1
SHORT COMMUNICATION
Copyright © 2010 Multimed Inc.
KEY WORDS
e g f r  overexpression, penile cancer
1.  INTRODUCTION
Penile cancer is a rare cancer in developed countries, 
but it has a higher incidence in developing countries 
such as Asia, Africa, and South America 1,2. Despite its 
rarity, the disease significantly affects the patient’s life 
when it does occur. Localized disease can be managed 
by surgical resection (partial or total penectomy) or 
penis-preserving surgery and radiotherapy. In patients 
with a higher T stage or grade, or clinically positive 
inguinal lymph nodes, an inguinal lymph node dis-
section is usually performed. If nonregional lymph 
nodes are involved or if metastatic disease is present, 
surgical cure cannot be obtained.
In these cases of advanced disease, surgery 
with or without radiation is often used for palliation 
and local control. Metastatic disease, which can 
involve distant lymph nodes, lung, liver, brain, and 
bone, is often managed with chemotherapy. Che-
motherapy in this situation has been poorly studied 
(no randomized trials), responses are often partial 
and of short duration, and therapy is associated 
with significant toxicity 3–7. Thus, it is imperative 
that new therapies be investigated for this rare but 
devastating disease.
Since the end of the 1980s, an understanding of 
the molecular biology of cancer has immensely in-
creased the understanding of tumour biology. Using 
this knowledge, scientists and clinicians are turning to 
novel treatments to exploit specific molecular targets. 
Tumour growth and progression depend on a number 
of pathways involving receptors at the cell membrane 
surface that control intracellular signalling pathways. 
One important pathway involves the cell-surface 
receptor epidermal growth factor receptor (e g f r ) 8. 
Epidermal growth factor and other ligands bind to 
and activate e g f r  to activate signalling pathways 
that regulate cell proliferation, migration, adhesion, 
differentiation, and apoptosis.
In a number of solid tumours, including brain, lung, 
breast, prostate, stomach, and head and neck, e g f r  can 
be overexpressed or mutated, leading to deregulation 
of related pathways. Overstimulation of e g f r -mediated 
signalling can contribute to uncontrolled cell division 
and thus to oncogenic signalling and tumour angiogen-
esis and metastasis, protecting cancer cells from under-
going apoptosis. In some malignancies, overexpression 
or excessive activation of e g f r  tends to be associated 
with a more aggressive malignant phenotype, with 
greater metastatic potential and worse prognosis 9–11.
To our knowledge, no studies have evaluated the 
expression of e g f r  in invasive squamous cell carci-
noma of the penis. Given e g f r  overexpression, and the 
success with e g f r -directed therapy in other tumours, 
we felt it worthwhile to pursue this area of research in 
penile cancer. Thus, the objective of the present study 
was to characterize the expression of e g f r  in cases 
of invasive squamous cell carcinoma of the penis. 
If overexpression were to be seen, then exploiting 
the e g f r  pathway as a therapeutic target in advanced 
penile cancer would be a rational approach.
2.  MATERIALS AND METHODS
Approval from the local research ethics board was 
obtained. Samples were selected from a pathology 
database of invasive penile squamous cell carci-
noma obtained through biopsy or surgical resection 
at the QEII Health Sciences Center, Halifax, during 
1997–2004.
Expression of e g f r  was evaluated and graded 
(0, 1+, 2+, 3+) by one trained pathologist using 
guidelines outlined in the commercially available 
immunohistochemical system kit EGFR PharmDx 
(DakoCytomation, Carpinteria, CA, U.S.A.). We used 
the EGFR PharmDx monoclonal mouse antibody 
(clone 2-18C9) with controls consisting of human cell 
lines CAMA-1 (negative control) and HT29 (positive 
control). Overexpression of e g f r  in the primary penile 
cancer was defined as any immunohistologic staining 
of tumour cell membranes above background level, 
whether circumferential staining was complete or 
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incomplete. No information on lymph node staging, 
lymphadenectomies, or e g f r  expression in lymph 
nodes was obtained.
3.  RESULTS
From the selected 8-year time period, 17 cases were 
obtained and studied. The median age of all patients 
was 66 years (range: 46–95 years).
All 17 cases overexpressed e g f r  (Table i, 
Figure 1). Expression was 3+ in 14 cases and 2+ in 
3 cases. Of the samples examined, 4 cases were also 
associated with carcinoma in situ (c i s ). In 2 cases, the 
c i s  also overexpressed e g f r , but to a lesser degree 
(1+) than did the invasive component. In the other 2 
cases, the c i s  did not overexpress e g f r .
In all cases, the adjacent normal squamous epithe-
lium demonstrated normal background e g f r  expres-
sion. Table i also presents the pathologic T stage and 
grade, but because overexpression of e g f r  was seen 
in all samples, no associations can be made between 
stage, grade, and overexpression.
Limitations to this study include its small sample 
size, which limited our ability to make any comments or 
conclusions about associations with T stage and grade. 
Also, we did not obtain information on lymph node me-
tastases or measure the phosphorylated form of e g f r .
4.  DISCUSSION AND CONCLUSIONS
Therapeutic advances in the area of advanced or 
metastatic penile cancer have been limited for several 
decades. Managing patients with this disease is a 
frustrating and disappointing endeavour because only 
short-lived partial responses can be obtained using 
traditional chemotherapy drugs.
Every sample of invasive squamous cell carci-
noma of the penis evaluated in this study expressed 
e g f r , with most showing 3+ overexpression. To date, 
several e g f r -targeted therapies have been developed. 
These include monoclonal antibodies that bind to 
e g f r  ligands (for example, cetuximab) and e g f r 
tyrosine kinase inhibitors (for example, gefitinib, 
erlotinib). As single agents, these drugs have been 
shown to have activity in several solid tumours 
including lung, head and neck, and colon 12–16. In 
phase iii lung and colon cancer trials, overall survival 
was improved. Current research is ongoing in these 
tumours to study the effects of chemotherapy in 
combination with e g f r -targeted therapy to improve 
outcomes even more.
Given the positive results in other tumours, the 
high degree of e g f r  overexpression in all samples 
in this study, and the lack of effective treatment for 
advanced penile cancer, further research into the e g f r  
pathway and invasive penile cancer are warranted. For 
example, determining whether lymph node or distant 
metastases from penile cancer also overexpress e g f r  
would be worthwhile, as would determining whether 
e g f r -targeted therapy has clinical activity in the set-
ting of advanced disease.
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